Maiken Keson-Brookes, the Chief Legal Officer and Secretary of Mural Oncology plc (NASDAQ:MURA), recently sold a portion of her holdings in the company. According to an SEC filing, Keson-Brookes sold 2,555 ordinary shares at a weighted average price of $3.27, totaling approximately $8,354. The sale comes as MURA trades near $3.18, down over 45% year-to-date, according to InvestingPro data. The transaction was conducted under a Rule 10b5-1 trading plan, which was established on September 20, 2024. Following this sale, Keson-Brookes retains ownership of 41,295 shares, which includes 38,705 unvested restricted stock units. The sale was carried out on December 23, 2024, and the filing was made public on December 26, 2024. While the company currently holds more cash than debt and maintains strong liquidity with a current ratio of 7.38, InvestingPro analysis reveals several additional insights about the company's financial health. Subscribers can access 8 more exclusive ProTips and comprehensive financial metrics to better understand MURA's market position.
In other recent news, Mural Oncology is set to release interim overall survival data from its ongoing ARTISTRY-7 study between late March and early June. The study combines the company's innovative engineered interleukin-2 cytokine, nemvaleukin alfa, with pembrolizumab in patients with platinum-resistant ovarian cancer. Furthermore, top-line results from cohort 2 of the Phase 2 ARTISTRY-6 study in mucosal melanoma are also anticipated. H.C. Wainwright, which recently initiated coverage on Mural Oncology with a Buy rating, believes in the potential of nemvaleukin alfa, despite past skepticism towards cytokine modalities. The firm anticipates multiple approvals in oncology for this class of treatments over the next five years. In other developments, Mural Oncology announced significant changes in its board of directors with the appointment of Sachiyo Minegishi and George Golumbeski. Both appointments are set to expire at the company's 2025 annual general meeting. As part of their compensation, both received an option to purchase over 15,000 ordinary shares at $3.38 per share. These are among the recent developments for Mural Oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.